Medicaid Providers Poised for a Comeback: BofA Upgrades Elevance Health, Centene, and Molina Healthcare

April 29, 2026 - 17:22

Bank of America Securities has issued a significant vote of confidence in the managed care sector, upgrading three major Medicaid-focused health insurers. The firm has raised its rating on Elevance Health and delivered a rare double upgrade to both Centene and Molina Healthcare, signaling that better days are ahead for companies serving government-sponsored health programs.

The upgrades come after a prolonged period of pressure on Medicaid providers, who have faced rising medical costs, regulatory uncertainty, and the unwinding of pandemic-era continuous enrollment requirements. BofA analysts now believe the worst is over for these companies, citing improving cost trends and a more stable regulatory environment. Elevance Health was upgraded from Neutral to Buy, while Centene and Molina Healthcare were both raised from Underperform to Buy—a notable two-step jump that reflects a fundamental shift in the outlook for these stocks.

According to the analysts, the recent headwinds that weighed on Medicaid margins are beginning to ease. Medical cost ratios, which had spiked as states redetermined eligibility and removed millions from the rolls, are expected to normalize. Additionally, the firms are benefiting from better pricing in their Medicare Advantage and commercial segments, providing a diversified revenue base. The upgrades suggest that the market has overly punished these stocks, creating an attractive entry point for investors.

For Molina Healthcare, the double upgrade highlights its strong positioning in the Medicaid market, with potential for membership growth as states resume more predictable enrollment patterns. Centene, which has undergone significant restructuring, is seen as having improved operational efficiency. Elevance Health, meanwhile, is praised for its scale and ability to manage costs across multiple lines of business. With the sector now trading at historically low valuations relative to earnings, BofA believes the risk-reward profile has shifted decisively in favor of buyers.